WebOct 29, 2024 · Fochon Pharmaceuticals, a subsidiary of Shanghai Fosun Pharmaceutical Co, has agreed to license FCN-338, a selective small-molecule BCL-2 inhibitor targeting hematological malignancies to Eli Lilly and Company, … WebCo-founder & CSO. Dr. Plattner co-founded Fochon in 2009 and is currently serving as Chief Science Officer. He received his B.S. degree from the University of Illinois and then …
Home_Fosun Pharma
WebShanghai Fosun Pharma (Group) Co., Ltd. (stock code: 600196.SH, 02196.HK), established in 1994, is a leading, innovation-driven international pharmaceutical and health industry … WebDec 13, 2024 · INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2024 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene … soiled dove underground denver seating chart
El regulador chino da luz verde a la emisión de acciones propuesta …
WebA unit of Shanghai Fosun Pharmaceutical has agreed to form a US$200 million joint venture with German partner BioNTech to build a plant in China capable of supplying up to 1 billion doses of coronavirus vaccine (BNT162b2) a year. Lead Product (s): BNT162b2 Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2 WebJul 1, 2024 · FCN-338 dramatically caused tumor regression in a dose-dependent manner. In the non-clinical studies, FCN-338 exhibits much improved pharmacokinetic … WebPhone Number +86 23 6320 6000 Fochon Pharmaceuticals offers small molecule therapeutic research and development in order to advance best-in-class medicines and enhance people's lives. It has a track record of advancing small molecule therapies with best-in-class potential for cancer and metabolic illnesses from discovery to clinical … soiled himself